Sun Pharma secures global rights to $3.7 billion PCSK9 cholesterol drug

Sun Pharmaceutical Industries announced a global licensing pact with U.S.-based LIB Therapeutics for Lerodalcibep, a once-monthly PCSK9 inhibitor that lowers LDL-cholesterol. Under the agreement, Sun Pharma gains exclusive rights to manufacture and market the drug outside the United States and China, entering a $3.7 billion market for PCSK9 inhibitors that has expanded at a 38 % compound annual growth rate through June 2026, according to IQVIA.

The European Union recently approved the medicine under the brand name Lyrokaul for adults with primary hypercholesterolaemia, inherited high cholesterol, and mixed dyslipidaemia. Europe alone represents $2.9 billion of the market, and the drug’s room-temperature storage for six months may improve patient convenience. Sun Pharma will handle commercialisation in its licensed territories and pursue approvals where needed, while LIB Therapeutics will receive an upfront sum, milestone payments and sales-based royalties, though financial details remain undisclosed.